Pharma startups like Pharnext are deploying machine learning to search for new therapeutic uses for “off patent” medications.
In the elegant quiet of the café at the Church of Sweden, a narrow Gothic-style building in Midtown Manhattan, Daniel Cohen is taking a break from explaining genetics. He moves toward the creaky piano positioned near the front door, sits down, and plays a flowing, flawless rendition of “Over the Rainbow.”
If human biology is the scientific equivalent of a complicated score, Cohen has learned how to navigate it like a virtuoso. Cohen was the driving force behind Généthon, the French laboratory that in December 1993 produced the first-ever “map” of the human genome. He essentially introduced Big Data and automation to the study of genomics, as he and his team demonstrated for the first time that it was possible to use super-fast computing to speed up the processing of DNA samples.
Scientists worldwide have built on Cohen’s insights, and Cohen himself, an MD with a Ph.D. in immunology, has gone on to success as a researcher and pharma executive. But a quarter-century later, genomics has yielded few of the kinds of paradigm-changing medical breakthroughs that many of its early innovators hoped for. Today, as chief executive and founder of Paris-based drug startup Pharnext, Cohen is striving to understand why that rainbow hasn’t led to a pot of gold.
“Any protein in the body has many different functions, not only one,” he says, returning from the piano to talk with me, “just as you are a person who has many functions in the population, not just one.” The phenomenon Cohen is describing is “pleiotropy,” the capacity of a single gene to have multiple, seemingly unrelated effects. It is one of the complexities of disease that has repeatedly frustrated medical researchers in their quest for therapies for the most stubborn illnesses.
Cohen not only appreciates pleiotropy’s significance: He believes that Pharnext and other drugmakers may soon exploit it—with a powerful boost from artificial intelligence. By embracing the body’s complexity, and by using A.I. to more methodically analyze and map the way the chain reactions of disease sweep through the body, he hopes to develop combinations of drugs tuned to attack a plethora of medical conditions.
Image Credit: Roberto Frankenberg
Thanks to Heinz V. Hoenen. Follow him on twitter: @HeinzVHoenen
News This Week
Frank Boehm: Publication of our new paper “Human Brain/Cloud Interface” in Frontiers in Neuroscience
Contributors: Nuno R. B. Martins, Amara Angelica, Yuriy Svidinenko, Frank J. Boehm, Ioan Opris, Mikhail A. Lebedev, Melanie Swan, Steven A. Garan, Jeffrey V. Rosenfeld, Tad Hogg, Robert A. Freitas Jr. et al Excerpt [...]
Abstract The progressive growth in nanotechnology approaches to diagnostics and therapeutics, especially for cancer, necessitates training physicians in nanoethics. This article explains why it is critical for medical education to include instruction in [...]
The rise of Candida auris embodies a serious and growing public health threat: drug-resistant germs. In May, an elderly man was admitted to the Brooklyn branch of Mount Sinai Hospital for abdominal surgery. A [...]
In a collaboration between the U.S. Department of Energy's Ames Laboratory and Northeastern University, scientists have developed a model for predicting the shape of metal nanocrystals or "islands" sandwiched between or below two-dimensional (2D) [...]
Should we be prepared to change the population composition of a species in order to wipe out a disease that is a terrible burden to mankind? During a well-attended working breakfast organised by the [...]
A new study led by Massachusetts General Hospital (MGH) investigators finds that radiation therapy may increase the uptake of therapeutic nanoparticles by glioblastomas, raising the possibility of using both growth-factor-targeted and immune-system-based therapies against [...]
Taking a cue from biological cells, researchers from MIT, Columbia University, and elsewhere have developed computationally simple robots that connect in large groups to move around, transport objects, and complete other tasks. This [...]
Nearly a third of physicians will be sued at least once in their careers — most commonly for an error in diagnosis. Medical errors are also the third-leading cause of death in the United [...]
Inventors and scientists have been continuously working towards reducing the size of technological components. Room-sized computers to laptops that are slimmer than a pane of glass? It’s done. Huge bulky telephones to smartphones that [...]
You have witnessed a variety of nano-devices that were designed for tasks including delivering medicines within the body. All of them used to move in a variety of ways. However, the latest nano-device is [...]
Netra Rajesh is an undergraduate Engineering Science student specializing in Biomedical Systems Engineering. She is currently on her Professional Experience Year (PEY) at the Massachusetts Institute of Technology where her research lies at the [...]